The subject of this publication is the conclusion of agreements in accordance with Section 130 a (8) SGB V on finished medicinal products with various active substances or combinations of active substances within the framework of a so-called “open house model”.

The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest contract start is September 1, 2021. Based on this, the contract period is a maximum of 24 months. The contract ends on 31.8.2023 regardless of the beginning of the contract.

If the AOK Hessen conducts an invitation to tender for exclusive contracts in the form of an open procedure for the active substances during the contract period, the

Publication of closed contracts ended according to the contractual regulations.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under I.1). A prerequisite for the conclusion of a contract is that the interested pharmaceutical company must complete and sign the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity; this publication is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under I.1). A prerequisite for the conclusion of a contract is that the interested pharmaceutical company must complete and sign the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity; this publication is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.

Under the provision of uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130 a (8) SGB V for the active substances mentioned in Section B. Interested pharmaceutical companies can contact the I.1. Request the participation documents and the contract from the contact address given. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. A contract is concluded with every pharmaceutical company that meets the eligibility requirements. This publication is not exclusive and is not a public contract within the meaning of Directive 2014/24 / EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to procurement law regulations, unless they are mandatory for legal reasons.